CMS Open Payments · Program Year 2024
PolarisAR Inc
PolarisAR Inc reported $25,931.40 across General Payments, Research, and Ownership to 11 physicians and teaching hospitals across 12 transactions.
- $25.9K
- All-tracks total
- 12
- Transactions
- 11
- Recipients
- #1491
- of 1,925 companies
PolarisAR Inc reported $25,931.40 across all CMS Open Payments tracks (General + Research + Ownership) to 11 physicians and teaching hospitals in Program Year 2024 - ranking #1491 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $22,581.40, averaging $2.4K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer polarisar-inc PolarisAR Inc
$25.9K · #1491/1,925 · 0.0% industry · PY2024
- TOT $25.9K
- RANK #1491
- SHARE 0.0%
- TXN 12
- RCP 11
- CAT 2
- GEN $22.6K
- TOP1 49.7%
- PY 2024
Volume peers
Nearest volume peer: Boehringer Ingelheim USA, Inc. ($26.0K)
PolarisAR Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for PolarisAR Inc
PolarisAR Inc ranks #1491 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $25,931.40 across 12 transactions to 11 physicians and teaching hospitals - $2.2K per transaction and $2.4K per recipient on average.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $20.7K across 10 transactions, 91.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
PolarisAR Inc made 2 types of general payments. "Consulting Fee" is the largest category at $20.7K, 91.8% of General Payments.
How PolarisAR Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $20.7K | 10 | 91.8% |
| Travel and Lodging | $1.8K | 1 | 8.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $22,581.40 (100.0%) of $22,581.40 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for PolarisAR Inc
The five named recipients with the highest reported General Payments from this company
- 1
Herbert John Cooper
$11,234.00 across 5 reported transactions
- 2
Nana owusu Sarpong
$9,500.00 across 5 reported transactions
- 3
Peter Aaron Gold
$1,847.40 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as PolarisAR Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about PolarisAR Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with PolarisAR Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Enduromed, Llc
Axis Spine Technologies Inc.
Sc Medica
Topcon Corporation
Aucta Pharmaceuticals, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.